Widya Mulyasasmita
Managing Partner at BEVC
United States
Overview
Work Experience
Co-Founder, Managing Partner
2023 - Current
Venture Capital firm investing in early stage companies at the intersection of science, engineering, and computation. www.bevc.com
Advisory Board Member
2024
Adjunct Lecturer, Bioengineering
2023
Founding Advisor
2020
Democratizing single cell biotechnology. Team is hiring! www.partillion.com
Partillion Bioscience is an early-stage life science company developing a functional single-cell analysis platform.
Raised $6,067,053.00 from +ND Capital, Vertical Venture Partners and Paladin Capital Group.
Board of Directors
2022 - 2023
Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.
Raised $100,000,000.00 from Myeloma Investment Fund, Multiple Myeloma Research Foundation, Northpond Ventures, Leaps by Bayer, B Capital, ATEM Capital Fund LP, Northpond Ventures, Bloom Burton & Co., Centre for Commercialization of Cancer Immunotherapy and Leaps by Bayer.
Investor and Board Observer
2022 - 2023
The company manufactures and sells the aprevo™ digital-to-device 3-D printed implant system for lumbar spine surgery.
Raised $96,985,000.00 from U.S. Venture Partners and B Capital.
Sr. Principal, Healthcare
2021 - 2023
B Capital Group is a venture capital firm that backs global entrepreneurs in the field of information technology.
Investor and Board Observer
2021 - 2023
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Raised $210,000,000.00 from Pavilion Capital, Revelation Partners, SR One, LSP BioVentures, Monashee Investment Management, B Capital, Atlas Venture, Sofinnova Partners, CaaS Capital Management and Pivotal bioVenture Partners.
Board of Directors
2021 - 2023
OncoMyx Therapeutics develops oncolytic immunotherapies to assist in creating an immune response and treat cancer.
Raised $50,000,000.00 from Delos Capital, Madison Partners, Xeraya Capital, City Hill Ventures, Boehringer Ingelheim Venture Fund, Lumira Ventures, B Capital, Korea Investment Partners and LYZZ Capital.
Vice President
2020 - 2021
Red Tree VC invests in early stage companies developing therapeutics addressing significant unmet needs in oncology, neurology, and immunology. Investor & Board Observer at: Acrigen Bioscience, Excellergy, Magnus Medical, Virsti Therapeutics